General inquiries: 314-454-6018
Research area Principle investigator(s) Email Brain tumors (neuro-oncology) Mohamed S. Abdelbaki, MD mohameda@wustl.edu Cancer predisposition Todd Druley, MD, PhD druley_t@wustl.edu Andrea Stacy, MS, CGC astacy@wustl.edu Hematological malignancy (leukemia & lymphoma) Jeffrey Magee MD, PhD mageej@wustl.edu Laura Schuettpelz MD, PhD schuettpelz_l@wustl.edu Hemostasis and thrombosis (clotting/bleeding disorders) David Wilson, MD, PhD wilson_d@wustl.edu Immune disorders Jeffrey Bednarski, MD, PhD bednarski_j@wustl.edu Sickle cell disease Monica Hulbert, MD monicahulbert@wustl.edu Solid tumors Frederick Huang, MD huang_f@wustl.edu Stem cell transplantation and cellular therapy Shalini Shenoy, MD shalinishenoy@wustl.edu Sima Bhatt, MD bhatts@wustl.edu Survivorship Robert Hayashi, MD hayashi_r@wustl.edu
Studies
Principal investigator Title Margaret Shatara, MD Phase 1/2 Study of Bempegaldesleukin in Combination with Nivolumab in Children, Adolescents, and Young Adults with Recurrent or Refractory Malignancies (PIVOT IO 020) Mohamed S. Abdelbaki, MD A Phase 2 Trial of Chemotherapy followed by Response-Based Whole Ventricular & Spinal Canal Irradiation (WVSCI) for Patients with Localized Non-Germinomatous Central Nervous System Germ Cell Tumor Robert Hayashi, MD Selinexor in Treating Younger Patients with Recurrent or Refractory Solid Tumors or High Grade Glioma Karen Gauvain, MD Study of RXDX-101 in Children with Recurrent of Refractory Solid Tumors and Primary CNS Tumors, with or without TRK, ROS1, or ALK Fusions Karen Gauvain, MD Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors Joshua Rubin, MD, PhD A Study Comparing Two Carboplatin Containing Regimens for Children and Young Adults with Previously Untreated Low Grade Glioma Karen Gauvain, MD Phase II Pediatric Study With Dabrafenib in Combination With Trametinib in Patients With HGG and LGG Joshua Rubin, MD, PhD Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Younger Patients With Newly Diagnosed Ependymoma Karen Gauvain, MD Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma Karen Gauvain, MD CA209-908 – Phase Ib/II Clinical Trial of Nivolumab Monotherapy and Nivolumab in Combination with Ipilimumab in Pediatric Subjects with High Grade Primary CNS Malignancies Karen Gauvain, MD PNOC 001 – Phase II Study of Everolimus for Recurrent or Progressive Low-Grade Gliomas in Children Karen Gauvain, MD H3.3K27M Peptide Vaccine for Children With Newly Diagnosed DIPG and Other Gliomas Karen Gauvain, MD PNOC013 – A Safety and Pharmacokinetic Study of Single Agent REGN2810 in Pediatric Patients with Relapsed or Refractory Solid or Central Nervous System (CNS) Tumors and a Safety and Efficacy Trial of REGN2810 in Combination with Radiotherapy in Pediatric Patients with Newly Diagnosed Diffuse Intrinsic Pontine Glioma, Newly Diagnosed High-Grade Glioma, or Recurrent High-Grade Glioma Karen Gauvain, MD Phase I-II Study of MEK162 for Children with Ras/Raf Pathway Activated Tumors Karen Gauvain, MD Modified Measles Virus (MV-NIS) for Children and Young Adults With Recurrent Medulloblastoma or Recurrent ATRT Karen Gauvain, MD Vemurafenib in Children With Recurrent/Refractory BRAFV600E-mutant Gliomas Joshua Rubin, MD, PhD Study Assessing the Feasibility of a Surgery and Chemotherapy-Only in Children With Wnt Positive Medulloblastoma Joshua Rubin, MD, PhD Cognitive Biomarkers in Pediatric Brain Tumor Patients Shalini Shenoy, MD ANBL1531: Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients with Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma Karen Gauvain, MD Expanded Access to ONC201 for Patients with H3 K27M-mutant and/or Midline High Grade Gliomas Karen Gauvain, MD REGN2810 in Pediatric Patients with Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination with Radiotherapy in Pediatric Patients with Newly Diagnosed or Recurrent Glioma Karen Gauvain, MD An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type I Karen Gauvain, MD Veliparib, Radiation Therapy, and Temozolimide in Treating Participants with Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600E Mutations Karen Gauvain, MD Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and Adults
Principal investigator Title Robert Hayashi, MD AAML18P1: Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia – Chronic Phase (CML-CP) Robert Hayashi, MD Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients with Down Syndrome Robert Hayashi, MD Trentinoin and Arsenic Trioxide in Treating Patients with Untreated Acute Promyelocytic Leukemia Robert Hayashi, MD A Phase II Study of Ruxolitinib with Chemotherapy in Children with Acute Lymphoblastic Leukemia Robert Hayashi, MD Blinatumomab in Treating Younger Patients with Relapsed B-Cell Acute Lymphoblastic Leukemia Robert Hayashi, MD Combination Chemotherapy in Treating Young Patients with Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations Robert Hayashi, MD A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma Robert Hayashi, MD Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) Robert Hayashi, MD A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin’s Lymphoma (cHL), Relapsed or Refractory From First Line Treatment Robert Hayashi, MD Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB or Stage IIIB-IVB Hodgkin Lymphoma Robert Hayashi, MD A Study of Pembrolizumab (MK-3475) in Pediatric Participants with an Advanced Solid Tumor or Lymphoma Robert Hayashi, MD Post Transplant Lymphoproliferative Disease: Analysis of Outcome to Chemotherapy Treatment Robert Hayashi, MD Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients with EBV-Positive Cluster of Differentiation (CD) 20-Positive Post-Transplant Lymphoproliferative Disorder Shalini Shenoy, MD A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma Jeffrey Magee, MD Matched Targeted Therapy for High-Risk Leukemias and MDS Robert Hayashi, MD A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years old, with Hodgkin’s Lymphoma (cHL), Relapsed or Refractory From First Line Treatment
Principal investigator Title Robert Hayashi, MD A Phase 1/2 Study of Tegavivint (IND#156033, NSC#826393) in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors Amy Armstrong, MD A Maintenance Protocol of Sirolimus in Combination with Metronomic Chemotherapy in Children with High-Risk Solid Tumors Frederick Huang, MD A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy with Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) plus VINO-CPO Maintenance in Patients with High Risk Rhabdomyosarcoma (HR-RMS) Frederick Huang, MD Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma Robert Hayashi, MD Selinexor in Treating Younger Patients with Recurrent or Refractory Solid Tumors or High Grade Gliomas Karen Gauvain, MD Study of RXDX-101 in Children with Recurrent of Refractory Solid Tumors and Primary CNS Tumors, with or without TRK, ROS1, or ALK Fusions Robert Hayashi, MD PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) Robert Hayashi, MD Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) Robert Hayashi, MD Active Surveillance, Bleomycin, Carboplatin, Etoposide, or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors Frederick Huang, MD Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma Todd Druley, MD, PhD International Pleuropulmonary Blastoma (PPB) Treatment and Biology Registry Alok Kothari, MD Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors With Sorafenib in Combination With Irinotecan Alok Kothari, MD Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors Robert Hayashi, MD Nivolumab with or without Ipilimumab in Treating Younger Patients with Recurrent or Refractory Solid Tumors or Sarcomas Robert Hayashi, MD WEE1 Inhibitor MK-1775 and Irinotecan Hydrochloride in Treating Younger Patients with Relapsed or Refractory Solid Tumors Robert Hayashi, MD A Study of Pembrolizumab (MK-3475) in Pediatric Participants with an Advanced Solid Tumor or Lymphoma Robert Hayashi, MD PI3K/mTOR Inhibitor LY3023414 in Treating Patients with Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders with TSC or PI3k/MTOR Mutations (A Pediatric MATCH Treatment Trial) Robert Hayashi, MD ADVL1614 – A Phase 1/2 Study of VX15/2503 (IND# 136181) in Children, Adolescents or Young Adults with Recurrent or Relapsed Solid Tumors Robert Hayashi, MD Prexasertib in Treating Pediatric Patients with Recurrent or Refractory Solid Tumors Robert Hayashi, MD Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patients with Recurrent or Refractory Solid Tumors Robert Hayashi, MD A Study of Ramucirumab (LY3009806) in Children with Refractory Solid Tumors Robert Hayashi, MD Pevonedistat, Irinotecan Hydrochloride, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma Robert Hayashi, MD Entinostat in Treating Pediatric Patients with Recurrent or Refractory Solid Tumors Robert Hayashi, MD Accelerated v’s Standard BEP Chemotherapy for Patients with Intermediate and Poor-risk Metastatic Germ Cell Tumours Robert Hayashi, MD Active Surveillance, Bleomycin, Carboplatin, Etoposide, or Cisplatin in Treating Pediatric and Adult Patients with Germ Cell Tumors Robert Hayashi, MD Pazopanib Paediatric Phase II Trial Children’s Oncology Group (COG) in Solid Tumors Robert Hayashi, MD Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma Robert Hayashi, MD Study of Kidney Tumors in Younger Patients Robert Hayashi, MD Accelerated v’s Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours (P3BEP) Robert Hayashi, MD Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) Robert Hayashi, MD Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) Robert Hayashi, MD Selumetinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Robert Hayashi, MD Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) Robert Hayashi, MD Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) Robert Hayashi, MD Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) Robert Hayashi, MD Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
Principal investigator Title A Pilot Study in the Treatment of Refractory EBV Infection with Related Donor EBV Cytotoxic T-Lymphocytes in Children, Adolescent, and Young Adult Recipients Peter Westervelt, MD, PhD; Shalini Shenoy, MD Clinical Transplant-related Long-term Outcomes of Alternative Donor Allogeneic Transplant (CTRL-ALT-D) Shalini Shenoy, MD NYMC 579: A Pilot Study in the Treatment of Refractory Adenovirus (ADV) Infection with Related Donor ADV Cytotoxic T-Lymphocytes (ADV-CTLs) in Children, Adolescents and Young Adult Recipients Shalini Shenoy, MD A Pilot Study in the Treatment of Refractory Cytomegalovirus (CMV) Infections with Related Donor CMV Specific Cytotoxic T-cells (CTLs) in Children, Adolescents, and Young Adult Recipients – NYMC 580 Shalini Shenoy, MD Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (STRIDE2) (BMT CTN 1503) Shalini Shenoy, MD Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders Jeffrey Bednarski, MD, PhD Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant Shalini Shenoy, MD Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases Shalini Shenoy, MD UVADEX® and ECP for the Treatment of Pediatric Patients With Steroid Refractory Acute Graft Versus Host Disease Shalini Shenoy, MD An Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant Robert Hayashi, MD Prevalence of Ototoxicity following Bone Marrow Transplantation and Stem Cell Transplantation in Pediatrics Andrew Cluster, MD Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid Tumors (LASCR) Shalini Shenoy, MD Haploidentical Bone Marrow Transplantation in Sickle Cell Patients (BMT CTN 1507) Shalini Shenoy, MD Optimizing Cord Blood and Haploidentical Aplastic Anemia Transplantation (BMT CTN 1502) (CHAMP) Sima Bhatt, MD CAR-T Cell Therapy for Acute Pre-B Leukemia and Lymphoma Jeffrey Bednarski, MD, PhD Reduced Intensity Transplant for Immune Deficiency Disorders (Immune Disorder HSCT Protocol) Shalini Shenoy, MD Phase ½ Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects with Chronic Graft Versus Host Disease (cGVHD) Shalini Shenoy, MD A Study Evaluating the Safety and Efficacy of the LentiGlobin BB305 Drug Product in Severe Sickle Cell Disease
Principal investigator Title Robert Hayashi, MD Long-Term Follow-Up of Patients Who Have Participated in Children’s Oncology Group Studies Joshua Rubin, MD, PhD Neuropsychological and Behavioral Testing in Younger Patients With Cancer Robert Hayashi, MD Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors Robert Hayashi, MD Prevalence of Ototoxicity following Bone Marrow Transplantation and Stem Cell Transplantation in Pediatrics Robert Hayashi, MD Childhood Cancer Survivor Study (CCSS) – Expansion Robert Hayashi, MD Knowledge and perceptions of infertility in adolescent female cancer survivors and parents Robert Hayashi, MD Late Onset and Asymmetric Sensorineural Hearing Loss in Pediatric Cancer Survivors Following Treatment with Cisplatin Containing Chemotherapy Regimens Caroline Mohrmann, PNP Patient, Family, and Provider Decision-Making in the Setting of Chemotherapy-Induced Hearing Loss Robert Hayashi, MD Effects of Modern Chemotherapy Regimens on Spermatogenesis and Steroidogenesis in Adolescent and Young Adult (AYA) Survivors of Osteosarcoma Miranda Camet Retrospective Review of Audiologic Test Results for Pediatric Patients with Beckwith-Wiedemann Syndrome and hemihypertrophy Shalini Shenoy, MD A Multi-center Retrospective Registry of Children with Sickle Cell Disease following Hematopoietic Cell Transplantation: a Sickle Transplant Alliance for Research (STAR) Project